期刊文献+

顺铂肾毒性相关机制及其防护研究现状 被引量:11

原文传递
导出
摘要 目的综述近年来国内外关于顺铂肾毒性机制及其防护措施的最新研究现状,为确立顺铂肾毒性临床有效防护措施提供依据。方法以肾脏中顺铂相关转运体、代谢酶及肾毒性相关信号传导机制和防护措施为线索,查阅整理国内外相关文献。结果顺铂肾毒性相关机制已从不同水平上被阐明,但防护措施大都是片面的,防护效果也有待临床检验。结论顺铂肾毒性防护措施的进一步研究应以肿瘤细胞或肿瘤患者为实验模型、综合考虑肾毒性各相关机制,最终确立具有较好肾毒性防护效果的临床顺铂化疗方案。
作者 张静 周文
出处 《中国药学杂志》 CAS CSCD 北大核心 2012年第22期1785-1789,共5页 Chinese Pharmaceutical Journal
  • 相关文献

参考文献70

  • 1VON HOFF D D, ROZENCWEIG M. cis-Diamminedichloroplati- hum( Ⅱ): a metal complex with significant anticancer activity [ J ]. Adv Pharmacol Chemother, 1979, 16:273-298.
  • 2刘华顶,王世亮,叶红杨,许健健,储成顶,宣凤琴.顺铂植入剂经皮肝植入治疗肝癌的药动学研究[J].中国药学杂志,2010,45(22):1753-1757. 被引量:3
  • 3SAAD A A, YOUSSEF M I, E1-SHENNAWY L K. Cisplatin in- duced damage in kidney genomic DNA and nephrotoxicity in male rats: The protective effect of grape seed proanthocyanidin extract [J]. Food and Chemical Toxicology, 2009, 47(7) :1499-1506.
  • 4WANG D, LIPPARD S J. Cellular processing of platinum anti- cancer drugs[ J]. Nat Rev Drug Discov, 2005,4(4) :307-320.
  • 5RAZZAQUE M S. Cisplatin nephropathy: Is cytotoxicity avoida- ble? [J] Nephrol Dial Transplant, 2007, 2(8) :2112-2116.
  • 6LIEBERTHAL W, TRIACA V, LEVINE J. Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: Apopto- sis vs necrosis[ J]. Am J Physiol, 1996, 270(4) :700-708.
  • 7FILIPSKI K K, LOOS W J, VERWEIJ J, et al. Interaction of cisplatin with the human organic cation transporter 2 [ J ]. Clin Cancer Res, 2008, 14(12) :3875-3880.
  • 8FILIPSKI K K, MATHIJSSEN R H, MIKKELSEN T S, et al. Contribution of organic cation transporter 2 ( OCT2 ) to cisplatin- induced nephrotoxicity[ J]. Clin Pharmacol Ther, 2009, 86(4) : 396-402.
  • 9WANG Z J, YIN O Q, TOMLINSON B, et al. OCT2 polymor- phisms and in vivo renal functional consequence: Studies with metformin and cimetidine [ J ]. Pharmacogenet Genomics, 2008, 18(7) :637-645.
  • 10CIARIMBOLI G, DEUSTER D, KNIEF A, et al. Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions [J] . Am J Pathol, 2010, 176(3) :1169-1180.

二级参考文献15

  • 1储成顶,成微,王世亮,刘飞,俞敏,鲍玉婷.缓释植入剂局部给药治疗系统的药动学模型[J].中国新药杂志,2004,13(7):613-616. 被引量:23
  • 2Ch. P(2005). vol Ⅱ [S]. suppl, 2005: 173-176.
  • 3BARABAS K, MILNER R, LURIE D,et al. Cisplatin: a review of toxicities and therapeutic applications [ J]. Vet Comp Oncol, 2008,6(1 ) : 1-18.
  • 4YAPP D T, LLOYD D K, ZHU J. Cisplatin delivery by biodegradable polymer implant is superior to systemic delivery by osmotic pump or ip injection in tumor-bearing mice[J]. Anticancer Drugs, 1998,9 (9) : 791-796.
  • 5GE Y Q ZHANG Y Q Lu G C et al.Simultaneous determination of cisplatin and etoposide in plasma and tissue by HPLC.药物分析杂志,2003,23(2):87-90.
  • 6GRYPARIS E C, HATZIAPOSTOLOU M, PAPADIMITRIOU E. Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer ceils [ J ]. Eur J Pharm Biopharm, 2007,67(1) : 1-8.
  • 7SUN Y, SHI Y K. Clinical Manual for Internal Medicine( 内科医学临床手册) [M]. 5^thed. Beijing: People's Medical Publishing House, 2008: 10-11.
  • 8FENG M,AN H J. Interstitial chemotherapy for liver,gall-bladder and pancreatic carcinomas. In Li Y,New technique of the microinvasive treatments against the liver, gall-bladder and pancreatic carcinomas(肝癌、胆囊和胰腺癌的微创治疗新技术) [ M]. Beijing: Beijing Science and Technology Press, 2009:211-241.
  • 9KIM J H ,KIM Y S ,PARK K. Antitumor efficacy of cisplatinloaded glycol chitosan nanoparticles in tumor-bearing mice [ J ]. J Controlled Release, 2008,127 : 4149.
  • 10BIASINO J,DOM NGUEZ J R,ALVARADO J. Hydrogen peroxide in basic media for whole blood sample dissolution for determination of its lead content by electrothermal atomization atomic absorption spectrometry [ J ]. Talanta, 2007,73 (5) : 962-964.

共引文献2

同被引文献124

引证文献11

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部